AVANIR PHARMACEUTICALS INVITES INVESTORS TO LISTEN TO THE BANK OF AMERICA 2006 HEALTH CARE CONFERENCE WEBCAST

San Diego, May 16, 2006 -- Avanir Pharmaceuticals (NASDAQ: AVNR) will be presenting at the Bank of America 2006 Health Care Conference on Wednesday, May 17, 2006 at 4:40 p.m. PT in Las Vegas.  Avanir's President and Chief Executive Officer, Eric Brandt, and Keith Katkin, Senior Vice President of Sales and Marketing will be presenting at the investor conference.

The presentation will be available via a live webcast accessible through Avanir's corporate website at www.avanir.com.  To access the webcast, log on to Avanir's site fifteen minutes prior to the presentation to register and download any necessary audio software.  An archive of the presentation will be available until June 2, 2006. 

About Avanir

Avanir Pharmaceuticals is focused on developing and commercializing novel therapeutic products for the treatment of chronic diseases.  Avanir's product candidates address therapeutic markets that include central nervous system and cardiovascular disorders, inflammation, and infectious diseases.  Avanir previously announced and published positive results from the two required Phase III clinical trials for Neurodex™, an investigational new drug for the treatment of involuntary emotional expression disorder currently under priority review with the FDA.  Additionally, Avanir has initiated a Phase III clinical trial for Neurodex as a potential treatment in patients with diabetic neuropathic pain, a second indication for Neurodex.  Avanir has active collaborations with two international pharmaceutical companies: Novartis International Pharmaceutical Ltd. for the treatment of inflammatory disease and AstraZeneca for the treatment of cardiovascular disease.  The Company's first commercialized product, abreva®, is marketed in North America by GlaxoSmithKline Consumer Healthcare and is the leading over-the-counter product for the treatment of cold sores.  Further information about Avanir can be found at www.avanir.com.

Avanir Pharmaceuticals Contacts:

Patrick O'Brien                                                   Patrice Saxon
858-622-5216                                                    858-622-5202
pobrien@avanir.com                                           psaxon@avanir.com

What do you think?
May 16, 2006